<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04772989</url>
  </required_header>
  <id_info>
    <org_study_id>ARC-12</org_study_id>
    <nct_id>NCT04772989</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies</brief_title>
  <official_title>A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcus Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcus Biosciences, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to&#xD;
      evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical&#xD;
      activity of AB308 in combination with zimberelimab (AB122) in participants with advanced&#xD;
      malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with Adverse Events</measure>
    <time_frame>From first study treatment administration until up to 90 days after the last dose (Approximately 1 year)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who experience a Dose Limiting Toxicity</measure>
    <time_frame>From first study treatment administration through Day 21 (Q3W arm) or Day 28 (Q4W arm)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of AB308</measure>
    <time_frame>Recorded at baseline (day 1 of cycle 1), during each of the first 5 cycles (each cycle is 21 days or 28 days) )and up to the first 16 cycles of treatment (up to 15 months), and 30 and 90 days post last dose (i.e. in total up to approximately 18 months).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of zimberelimab</measure>
    <time_frame>Recorded at baseline (day 1 of cycle 1), during each of the first 5 cycles (each cycle is 21 days or 28 days) and up to the first 16 cycles of treatment (up to 15 months), and 30 and 90 days post last dose (i.e. in total up to approximately 18 months).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with anti-drug antibodies to AB308</measure>
    <time_frame>Recorded at baseline (day 1 of cycle 1), during each of the first 4 cycles (each cycle is 21 days or 28 days) and up to the first 16 cycles of treatment (up to 15 months), and 30 and 90 days post last dose (i.e. in total up to approximately 18 months).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with anti-drug antibodies to zimberelimab</measure>
    <time_frame>Recorded at baseline (day 1 of cycle 1), during each of the first 4 cycles (each cycle is 21 days or 28 days) and up to the first 16 cycles of treatment (up to 15 months), and 30 and 90 days post last dose (i.e. in total up to approximately 18 months).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Objective Response</measure>
    <time_frame>From study enrollment until participant discontinuation, first occurrence of progressive disease, or death from any cause, whichever occurs first (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>From the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Disease Control (complete response, partial response, or stable disease) for &gt;6 months</measure>
    <time_frame>From study enrollment until disease progression or loss of clinical benefit (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>NSCLC</condition>
  <condition>Melanoma</condition>
  <condition>Cervical Cancer</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>DLBCL</condition>
  <condition>Gastric Cancer</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Q3W Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses of AB308 in combination with zimberelimab (360 mg) will be given every 3 weeks in participants with advanced malignancies.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Q4W Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses of AB308 in combination with zimberelimab (480 mg) will be given every 4 weeks in participants with advanced malignancies.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with in participants with locally advanced or metastatic NSCLC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with melanoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with metastatic gastric, or gastroesophageal junction, or esophageal cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with cervical cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with hematological malignancies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB308</intervention_name>
    <description>Administered as specified in the treatment arm</description>
    <arm_group_label>Dose Escalation Q3W Cohorts</arm_group_label>
    <arm_group_label>Dose Escalation Q4W Cohorts</arm_group_label>
    <arm_group_label>Dose Expansion Cohort 1</arm_group_label>
    <arm_group_label>Dose Expansion Cohort 2</arm_group_label>
    <arm_group_label>Dose Expansion Cohort 3</arm_group_label>
    <arm_group_label>Dose Expansion Cohort 4</arm_group_label>
    <arm_group_label>Dose Expansion Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zimberelimab</intervention_name>
    <description>Administered as specified in the treatment arm</description>
    <arm_group_label>Dose Escalation Q3W Cohorts</arm_group_label>
    <arm_group_label>Dose Escalation Q4W Cohorts</arm_group_label>
    <arm_group_label>Dose Expansion Cohort 1</arm_group_label>
    <arm_group_label>Dose Expansion Cohort 2</arm_group_label>
    <arm_group_label>Dose Expansion Cohort 3</arm_group_label>
    <arm_group_label>Dose Expansion Cohort 4</arm_group_label>
    <arm_group_label>Dose Expansion Cohort 5</arm_group_label>
    <other_name>AB122</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Performance status score of 0 or 1&#xD;
&#xD;
          -  Measurable disease as per radiographic evaluation&#xD;
&#xD;
          -  Disease-specific criteria for dose escalation:&#xD;
&#xD;
               -  Participants with any type of solid tumor for which no treatment is currently&#xD;
                  available, or&#xD;
&#xD;
               -  Participants with non-Hodgkin Lymphoma that has progressed on prior chemotherapy&#xD;
                  and have not or are unable to receive stem cell transplant. transfer&#xD;
&#xD;
               -  Participants may have received up to 5 prior anti-cancer therapies and an&#xD;
                  unlimited number of prior hormonal therapies.&#xD;
&#xD;
          -  Disease-specific criteria for dose-expansion Cohort 1:&#xD;
&#xD;
               -  Participants with previously untreated locally advanced or metastatic NSCLC with&#xD;
                  a high PD-L1 expression&#xD;
&#xD;
          -  Disease-specific criteria for dose-expansion Cohort 2:&#xD;
&#xD;
               -  Participants with metastatic melanoma with at least one prior anti-cancer therapy&#xD;
                  and progression after PD-L1 therapy&#xD;
&#xD;
          -  Disease-specific criteria for dose-expansion Cohort 3:&#xD;
&#xD;
               -  Participants with metastatic gastric, or gastroesophageal junction, or esophageal&#xD;
                  cancer with at least 1 prior chemotherapy and no prior PD-(L)1 therapy.&#xD;
&#xD;
          -  Disease-specific criteria for dose-expansion Cohort 4:&#xD;
&#xD;
               -  Participants with metastatic cervical cancer with at least 1 prior chemotherapy&#xD;
                  and no prior PD-(L)1 therapy.&#xD;
&#xD;
          -  Disease-specific criteria for dose-expansion Cohort 5&#xD;
&#xD;
               -  Participants with diffuse large B-cell lymphoma (DLBCL) with at least 2 prior&#xD;
                  anti-cancer therapies and have not or are unable to receive allogenic stem cell&#xD;
                  transplant&#xD;
&#xD;
               -  Participants with multiple myeloma with at least 3 prior anti-cancer therapies&#xD;
                  and for whom no treatment is currently available.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of trauma or major surgery within 28 days prior to the first dose of study&#xD;
             treatment.&#xD;
&#xD;
          -  Prior treatment with an anti-TIGIT antibody.&#xD;
&#xD;
          -  Any active or prior autoimmune disease that required treatment within 3 years of the&#xD;
             first dose of study treatment.&#xD;
&#xD;
          -  Prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic&#xD;
             agents, or use of other investigational drugs within 28 days before first dose of&#xD;
             study treatment.&#xD;
&#xD;
          -  Discontinued prior immunotherapy for immune related adverse events with a high&#xD;
             severity.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Arcus Biosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arcus Biosciences</last_name>
    <phone>510-694-6200</phone>
    <email>clinicaltrials@arcusbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054-4502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045-2545</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Sites</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909-6520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Goshen Health System</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202-3700</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3729</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Peggy and Charles Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Onocology - Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START South Texas Accelerated Research Therapeutics - San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START South Texas Accelerated Research Therapeutics - Mountain Region</name>
      <address>
        <city>West Valley City</city>
        <state>Utah</state>
        <zip>84119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin - Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

